摘要
目的:研究2型糖尿病(T2DM)患者使用利拉鲁肽致胃肠道不良反应(GIAR)的危险因素。方法:采用回顾性研究方法,以某院2019年1~12月收治的首次使用利拉鲁肽的T2DM患者为研究对象,依据1个疗程(3个月)内是否发生GIAR分为两组。通过医院信息系统(HIS)提取各组患者一般资料、检验指标、用药情况,运用Logistic回归分析方法筛选T2DM患者使用利拉鲁肽致GIAR的危险因素。结果:共有196例患者纳入分析。46例(23.4%)使用利拉鲁肽后发生GIAR,其中继续疗程的有34例(17.3%),中止疗程12例(6.1%)。单因素分析结果显示,发生GIAR组和未发生GIAR组联用α-糖苷酶抑制药、联用胰岛素、伴随消化道疾病的患者人数分布的差异均有统计学意义(P<0.05或0.01),Logistic回归分析结果显示,联用α-糖苷酶抑制药[OR=2.917,95%CI(1.007,8.453),P=0.049]和伴随消化道疾病[OR=3.469,95%CI(1.226,9.817),P=0.019]是T2DM患者使用利拉鲁肽治疗中致GIAR的独立危险因素。结论:联用α-糖苷酶抑制药和伴随消化道疾病是造成患者发生GIAR的独立危险因素,需要制定合适的给药方案或选择其他降糖药物。
Objective:To analysis the risk factors for the gastrointestinal adverse reactions(GIAR) induced by liraglutide in type 2 diabetes patients. Methods:A retrospective study was conducted. The type 2 diabetes patients treated by liraglutide from January to December 2019 were devided into two groups according to GIAR or not within 3 months of treatment. Datas were obtained from a hospital information system(HIS), including patients’ general datas, laboratory test index and medications. Logistic regression model was used to identify risk factors associated with GIAR induced by liraglutide in type 2 diabetes patients. Results:A total of 196 patients were included in the study. GIAR occurred in 46 cases(23.4%) after using liraglutide. 34 cases(17.3%) still adhered to the course of treatment, 12 cases(6.1%) could not adhere to the course of treatment. The result of univariate analysis showed that there were significant differences in the distribution of patients with combined α-glucosidase inhibitor, combined insulin and gastrointestinal diseases between GIAR group and non GIAR group(P<0.05 or 0.01). The result of logistic regression analysis showed that α-glucosidase inhibitor use(OR=2.917, 95%CI 1.007 to 8.453, P=0.049) and gastrointestinal disease(OR=3.469, 95%CI 1.226 to 9.817, P=0.019) were the risk factors of GIAR. Conclusion:The combination of α-glucosidase inhibitor and concomitant gastrointestinal diseases are independent risk factors for GIAR. It is necessary to choose an appropriate method of dosage regimen or other types of hypoglycemic agents.
作者
张冬琴
张云轩
刘美璇
沈杰
周海峰
吴建博
高宁舟
张敏
宋钟娟
Zhang Dongqin;Zhang Yunxuan;Liu Meixuan;Shen Jie;Zhou Haifeng;Wu Jianbo;Gao Ningzhou;Zhang Min;Song Zhongjuan(Department of Pharmacy,Huadong Hospital Affiliated to Fudan University,Shanghai 200040,China;Department of Respiratory Disease,Dongfang Hospital Affiliated to Tongji University)
出处
《药物流行病学杂志》
CAS
2021年第10期670-673,共4页
Chinese Journal of Pharmacoepidemiology
基金
上海市药学会科研项目(编号:2017-YY-02)。
关键词
利拉鲁肽
胃肠道不良反应
2型糖尿病
危险因素
Liraglutide
Gastrointestinal adverse reaction
Type 2 diabetic mellitus
Risk factors
